Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (581-590 of 616) with videos related to

Pageof 62
Sort By:
Circulation|September 5, 2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HFKieran F Docherty, Pardeep S Jhund, Inder Anand, et al.
Nature Medicine|August 27, 2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trialBarry A Borlaug, Dalane W Kitzman, Melanie J Davies, et al.
European Journal of Heart Failure|August 25, 2017
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitorsJaved Butler, Carine E Hamo, Gerasimos Filippatos, et al.
Circulation|May 19, 2026
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV TrialBrian A Bergmark, Erin A Bohula, Nicholas A Marston, et al.
Circulation|August 30, 2025
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart FailureDavid D Berg, Siddharth M Patel, Paul M Haller, et al.
The Canadian Journal of Cardiology|November 16, 2020
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial FibrillationJason G Andrade, Martin Aguilar, Clare Atzema, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
Iscience|August 31, 2021
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19Andrew Kosmopoulos, Deepak L Bhatt, Gus Meglis, et al.
The New England Journal of Medicine|November 14, 2017
Restrictive or Liberal Red-Cell Transfusion for Cardiac SurgeryC David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
Pageof 62

Showing results (581-590 of 616) with videos related to

Sort By:
Pageof 62
Circulation|September 5, 2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HFKieran F Docherty, Pardeep S Jhund, Inder Anand, et al.
Nature Medicine|August 27, 2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trialBarry A Borlaug, Dalane W Kitzman, Melanie J Davies, et al.
European Journal of Heart Failure|August 25, 2017
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitorsJaved Butler, Carine E Hamo, Gerasimos Filippatos, et al.
Circulation|May 19, 2026
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV TrialBrian A Bergmark, Erin A Bohula, Nicholas A Marston, et al.
Circulation|August 30, 2025
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart FailureDavid D Berg, Siddharth M Patel, Paul M Haller, et al.
The Canadian Journal of Cardiology|November 16, 2020
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial FibrillationJason G Andrade, Martin Aguilar, Clare Atzema, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
Iscience|August 31, 2021
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19Andrew Kosmopoulos, Deepak L Bhatt, Gus Meglis, et al.
The New England Journal of Medicine|November 14, 2017
Restrictive or Liberal Red-Cell Transfusion for Cardiac SurgeryC David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
Pageof 62